Final Operational Milestone #4

Ankasa has

1) Successfully developed ART352-L, a liposomal formulation of recombinant human WNT3A protein, that is applied ex vivo, to harvested autologous bone graft (autograft) to enhance the osteogenic properties of bone autografts through activation of the target genes of the Wnt pathway.

2) Successfully submitted an IND to FDA for use of ART352-L in spinal fusion procedures. Ankasa also completed all clinical startup activities required to initiate the Phase 1/2a clinical trial once IND is cleared.